Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiTE as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation
NCT07706205Phase 1Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, open-label trial of blinatumomab and teclistamab in ABO incompatibility (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Blood group antibody titer. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
blinatumomabteclistamab
03
Conditions
ABO incompatibility
Beyond the preview
Go deeper on NCT07706205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07706205.